This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furman, P A Articles by Schaffer, P A Search for Related Content PubMed PubMed Citation Articles by Furman, P A Articles by Schaffer, P A

 Previous Article  |  Next Article 

J Virol. 1981 December; 40(3): 936-941

Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities.

ABSTRACT

The biochemical properties of four acyclovir-resistant mutants are described. Two of these mutants, PAAr5 and BWr, specified nucleotidyl transferase (DNA polymerase) activities which were less sensitive to inhibition by acyclovir triphosphate than their wild-type counterparts. Another mutant, IUdRr, exhibited reduced ability to phosphorylate acyclovir. The fourth mutant, ACGr4, both induced an altered DNA polymerase and failed to phosphorylate appreciable amounts of acyclovir. BWr, a new acyclovir-resistant mutant derived from the Patton strain of herpes simplex virus type 1, induced a DNA polymerase resistant to inhibition by acyclovir triphosphate, but, unlike the polymerases induced by PAAr5 and ACGr4, still sensitive to phosphonoacetic acid. Resistance of BWr to acyclovir mapped close to the PAAr locus and was separable from mutations in the herpes simplex virus thymidine kinase gene by recombination analysis.

This article has been cited by other articles:

• Duan, J., Liuzzi, M., Paris, W., Liard, F., Browne, A., Dansereau, N., Simoneau, B., Faucher, A.-M., Cordingley, M. G. (2003). Oral Bioavailability and In Vivo Efficacy of the Helicase-Primase Inhibitor BILS 45 BS against Acyclovir-Resistant Herpes Simplex Virus Type 1. Antimicrob. Agents Chemother. 47: 1798-1804 [Abstract] [Full Text]  
• Parcells, M. S., Lin, S.-F., Dienglewicz, R. L., Majerciak, V., Robinson, D. R., Chen, H.-C., Wu, Z., Dubyak, G. R., Brunovskis, P., Hunt, H. D., Lee, L. F., Kung, H.-J. (2001). Marek's Disease Virus (MDV) Encodes an Interleukin-8 Homolog (vIL-8): Characterization of the vIL-8 Protein and a vIL-8 Deletion Mutant MDV. J. Virol. 75: 5159-5173 [Abstract] [Full Text]  
• Duan, J., Liuzzi, M., Paris, W., Lambert, M., Lawetz, C., Moss, N., Jaramillo, J., Gauthier, J., Déziel, R., Cordingley, M. G. (1998). Antiviral Activity of a Selective Ribonucleotide Reductase Inhibitor against Acyclovir-Resistant Herpes Simplex Virus Type 1 In Vivo. Antimicrob. Agents Chemother. 42: 1629-1635 [Abstract] [Full Text]  
• Elion, G. (1989). The purine path to chemotherapy. Science 244: 41-47 [Abstract]